Abstract Library

#2219 24 Hour Urinary 5-Hydroxyindoleacetic Acid Levels in Patients with Non-Functioning Pancreatic Neuroendocrine Tumors

Introduction: The secretion of urinary 5-Hydroxyindoleacetic Acid (u5-HIAA) by non-functioning PNETs (NF-PNET) has rarely been reported, and the data on the association between u5-HIAA levels and disease burden is scant.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Tirosh A

Authors: Tirosh A, Papadakis G, Sadowsi S, Patel D, Nilubol N,

Keywords: 5-HIAA, PNET, Secretion, Biomarker,

#2188 Predictive Markers of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETS)

Introduction: NET are relatively rare and up to still far from fully studied pathology. The frequency of NET GEP does not exceed 2% of all tumors of this localization.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Issaeva S, Khalimova Z, Safarova M, Gumarova A, Yuldashev A,

Keywords: gastroenteropancreatic neuroendocrine tumors, morphology, clinical,

#2155 Menstrual Dysfunction in Women with Prolactinomas

Introduction: Hyperprolactinemia syndrome (HPS) is a set of symptoms with typical increase in serum prolactin accompanied by galactorrhea, hypogonadism and potential infertility

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Safarova M, Khalimova Z, Axmedova S, Issaeva S, Gumarova A,

Keywords: prolactinoma, hyperprolactinemia, dopamine agonists,

#1918 Case Study: Immunotherapy in a Young Adult with Atypical Neuroendocrine Tumour

Introduction: Use of immunotherapy PD-1 antibody has emerged as a novel therapeutic option for treating multiple solid tumors. In the setting of neuroendocrine tumors (NETs), little is known. Currently, trials are underway investigating its use in high-grade NETs, but outcomes remain to be seen

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Kavan P

Authors: Stavrides-Eid M, Soo Rho Y, Barrera I, Kavan P,

Keywords: thymic neuroendocrine tumour, pembrolizumab, atypical carcinoid, NETs,

#1821 Long-Term Efficacy and Safety with Lanreotide Autogel/Depot (LAN) from CLARINET and Open-Label Extension (OLE) Studies

Introduction: LAN 120mg has been shown to significantly prolong progression-free survival (PFS) in patients (pts) with gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Phan A

Authors: Phan A, Pavel M, Caplin M, Wolin E, Mirakhur B,

Keywords: lanreotide,